Latest News and Press Releases
Want to stay updated on the latest news?
-
Reported Full Year 2023 total revenues of 2% growth at €48.5 millionSecured approximately USD 20 million – strengthening cash position and expanding relationship with Lifera, a biopharma company owned...
-
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
-
First half 2023 total revenues with double-digit growth of 15.1% at €24.6 millionBoth Pharma and Diagnostics segments deliver strong performance, reaffirming full year 2023 guidance for total revenue...
-
ARLINGTON, Va., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Edge Total Intelligence Inc. (TSXV: CTRL, OTC: UNFYF, FSE: Q5i)(“edgeTI”, “we”, “our” or the “Company”), a leader in real-time digital operations,...
-
Full Year 2022 total revenues with double-digit growth of 12% at €47.5 million, in line with prior guidanceSignificant expansion of gross profit margin from 32% to 42% and ongoing cost control...
-
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
-
- Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments, Exceeds Guidance - Focus on Pharma and Diagnostics to Position for Strong Performance in 2022 - Closed $62 Million...
-
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to...
-
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
-
SAN JOSE, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Nubeva Technologies Ltd. ("Nubeva" or the "Company") (TSX-V: NBVA), announces its unaudited consolidated financial statements for the second...